Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Obesity-Driven Endometrial Cancer
NCT07065552Phase 1Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Apr 2026
- Primary completion
- Jul 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirzepatide in endometrial cancer (EC) and obesity, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Change in Proliferation up to 6 weeks. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)obesity
Beyond the preview
Go deeper on NCT07065552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07065552.